Actinium Pharmaceuticals, Inc.
(NYSE Amex Equities : ATNM)

... ...
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 12.20%147.000.0%$2706.27m
BNGOBioNano Genomics, Inc. 28.37%12.580.0%$2680.39m
GILDGilead Sciences, Inc. 1.82%68.161.0%$679.44m
AMGNAmgen, Inc. 1.42%257.101.3%$584.68m
REGNRegeneron Pharmaceuticals, Inc. 1.94%548.202.7%$502.24m
ALXNAlexion Pharmaceuticals, Inc. 1.00%161.322.0%$478.99m
CRSPCRISPR Therapeutics AG -3.85%181.240.6%$478.16m
ILMNIllumina, Inc. 3.63%421.003.5%$442.75m
NVAXNovavax, Inc. 3.53%131.4692.9%$427.52m
VRTXVertex Pharmaceuticals, Inc. 1.57%241.311.9%$385.00m
SRPTSarepta Therapeutics, Inc. -2.17%96.1113.8%$366.91m
BIIBBiogen, Inc. 2.26%275.541.7%$334.24m
BNTXBioNTech SE 2.00%110.610.0%$314.96m
EXASEXACT Sciences Corp. 2.62%153.9319.6%$267.92m
PACBPacific Biosciences of California, Inc. -3.93%35.957.4%$219.94m

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY.